Safety, Tolerability, and Pharmacokinetics of β-Cryptoxanthin Supplementation in Healthy Women: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial.
Asian women
carotenoids
fecal microbiome
gene expression
mood
physical activity
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
16 May 2023
16 May 2023
Historique:
received:
12
04
2023
revised:
04
05
2023
accepted:
09
05
2023
medline:
29
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
β-cryptoxanthin is a dietary carotenoid for which there have been few studies on the safety and pharmacokinetics following daily oral supplementation. 90 healthy Asian women between 21 and 35 years were randomized into three groups: 3 and 6 mg/day oral β-cryptoxanthin, and placebo. At 2, 4, and 8 weeks of supplementation, plasma carotenoid levels were measured. The effects of β-cryptoxanthin on blood retinoid-dependent gene expression, mood, physical activity and sleep, metabolic parameters, and fecal microbial composition were investigated. β-cryptoxanthin supplementation for 8 weeks (3 and 6 mg/day) was found to be safe and well tolerated. Plasma β-cryptoxanthin concentration was significantly higher in the 6 mg/day group (9.0 ± 4.1 µmol/L) compared to 3 mg/day group (6.0 ± 2.6 µmol/L) ( Oral β-cryptoxanthin supplementation over 8 weeks lead to high plasma concentrations of β-cryptoxanthin, with no impact on other carotenoids, and was well tolerated in healthy women.
Sections du résumé
BACKGROUND
BACKGROUND
β-cryptoxanthin is a dietary carotenoid for which there have been few studies on the safety and pharmacokinetics following daily oral supplementation.
METHODS
METHODS
90 healthy Asian women between 21 and 35 years were randomized into three groups: 3 and 6 mg/day oral β-cryptoxanthin, and placebo. At 2, 4, and 8 weeks of supplementation, plasma carotenoid levels were measured. The effects of β-cryptoxanthin on blood retinoid-dependent gene expression, mood, physical activity and sleep, metabolic parameters, and fecal microbial composition were investigated.
RESULTS
RESULTS
β-cryptoxanthin supplementation for 8 weeks (3 and 6 mg/day) was found to be safe and well tolerated. Plasma β-cryptoxanthin concentration was significantly higher in the 6 mg/day group (9.0 ± 4.1 µmol/L) compared to 3 mg/day group (6.0 ± 2.6 µmol/L) (
CONCLUSIONS
CONCLUSIONS
Oral β-cryptoxanthin supplementation over 8 weeks lead to high plasma concentrations of β-cryptoxanthin, with no impact on other carotenoids, and was well tolerated in healthy women.
Identifiants
pubmed: 37242207
pii: nu15102325
doi: 10.3390/nu15102325
pmc: PMC10222860
pii:
doi:
Substances chimiques
Vitamin A
11103-57-4
Beta-Cryptoxanthin
0
Carotenoids
36-88-4
beta Carotene
01YAE03M7J
Lutein
X72A60C9MT
Zeaxanthins
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : DSM Nutritional Products
ID : NA
Références
Soc Psychiatry Psychiatr Epidemiol. 2011 Jul;46(7):635-41
pubmed: 20422399
FASEB J. 2010 Jun;24(6):1656-66
pubmed: 20061533
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Nutr Rev. 2016 Feb;74(2):69-82
pubmed: 26747887
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Am J Clin Nutr. 2005 Sep;82(3):685-93
pubmed: 16155284
Food Nutr Res. 2020 Dec 28;64:
pubmed: 33447180
Biol Pharm Bull. 2019;42(8):1402-1408
pubmed: 31366875
Am J Clin Nutr. 2013 Nov;98(5):1200-8
pubmed: 24004891
Mech Ageing Dev. 2007 Nov-Dec;128(11-12):594-600
pubmed: 17916375
Med Sci Sports Exerc. 2014 Sep;46(9):1816-24
pubmed: 24887173
N Engl J Med. 1995 Nov 23;333(21):1369-73
pubmed: 7477116
Br J Nutr. 2006 Feb;95(2):358-65
pubmed: 16469154
BMC Gastroenterol. 2020 Oct 20;20(1):349
pubmed: 33081717
J Nutr. 2011 May;141(5):903-13
pubmed: 21451127
Br J Nutr. 2014 Dec 28;112(12):2041-8
pubmed: 25345663
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
ISME J. 2017 Dec;11(12):2639-2643
pubmed: 28731476
J Agric Food Chem. 2022 Oct 26;70(42):13592-13601
pubmed: 36214842
Cancer Sci. 2014 Jun;105(6):736-43
pubmed: 24673770
ISME J. 2010 Jan;4(1):17-27
pubmed: 19710709
Nutrients. 2019 May 17;11(5):
pubmed: 31108934
J Pers Assess. 1985 Feb;49(1):71-5
pubmed: 16367493
Clin Chem. 2003 Dec;49(12):2056-66
pubmed: 14633878
Br J Nutr. 2016 Mar 28;115(6):1033-42
pubmed: 26856420
Nutr Metab Cardiovasc Dis. 2022 Dec;32(12):2811-2821
pubmed: 36184364
Yakugaku Zasshi. 2016;136(9):1255-62
pubmed: 27592828
PLoS One. 2012;7(12):e52643
pubmed: 23285126
Nutr Res. 2019 Nov;71:65-71
pubmed: 31757627
Eur J Nutr. 2021 Mar;60(2):703-714
pubmed: 32435993
BMJ Open Diabetes Res Care. 2015 Dec 01;3(1):e000147
pubmed: 26688736
J Mol Neurosci. 2013 Oct;51(2):478-84
pubmed: 23955709
J Sci Food Agric. 2015 Jul;95(9):1786-94
pubmed: 25270992
Chin J Cancer Res. 2020 Dec 31;32(6):755-767
pubmed: 33446998
Lipids Health Dis. 2012 May 14;11:52
pubmed: 22584034
J Food Sci. 2021 Feb;86(2):602-613
pubmed: 33449409
Psychopharmacol Bull. 1993;29(2):321-6
pubmed: 8290681
Nutr Metab Cardiovasc Dis. 2014 Oct;24(10):1090-6
pubmed: 24909799
J Affect Disord. 2021 Mar 1;282:41-45
pubmed: 33388472
Nat Methods. 2018 Nov;15(11):847-848
pubmed: 30377368
Am J Epidemiol. 1985 Jul;122(1):51-65
pubmed: 4014201
Br J Clin Psychol. 2003 Jun;42(Pt 2):111-31
pubmed: 12828802
BMC Bioinformatics. 2004 Aug 19;5:113
pubmed: 15318951
Nutrients. 2016 Aug 27;8(9):
pubmed: 27618909
J Nutr. 2002 Sep;132(9 Suppl):2920S-2926S
pubmed: 12221270
Microbiome. 2018 May 17;6(1):90
pubmed: 29773078
Int J Dermatol. 2003 Mar;42(3):178-81
pubmed: 12653910
J Hypertens. 2019 Dec;37(12):2371-2379
pubmed: 31356404
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
Scand J Med Sci Sports. 2017 Dec;27(12):1814-1823
pubmed: 27878845
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
Teratology. 2000 Oct;62(4):214-26
pubmed: 10992263